Please login to the form below
Seattle Generics
This page shows the latest Seattle Generics news and features for those working in and with pharma, biotech and healthcare.
Seattle Genetics signs $2bn deal for Immunomedics' cancer drug
Immunomedics has signed up Seattle Genetics as the licensee for its triple-negative breast cancer (TNBC) drug IMMU-132, getting $300m upfront and another $1.7bn in possible milestone payments. ... Seattle Genetics will handle the running of a proposed
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account Director
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
-
Account Manager
-
£Competitive Salary
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
-
Senior External Communications Lead
-
£Competitive Salary
-
Senior Medical Writer
-
Salary TBC
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
-
Account Director, Medical Education
-
Salary TBC
-
Senior Account Manager
-
Salary TBC
- China backs use of Roche’s Actemra for coronavirus
- Novartis forms coronavirus alliance with life sciences companies
- FDA approves Roche’s Actemra COVID-19 trial
- UK biotech Synairgen to begin COVID-19 trial of lead candidate
- COVID-19: Novel coronavirus remains stable on surfaces for hours
- Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19
- Sanofi doses first patient in global Kevzara COVID-19 trial
- Behaviour change – is there something missing?
- Lundbeck drops Parkinson’s drug acquired in €905m deal
- AZ’s Imfinzi gets US OK in small cell lung cancer, challenging Tecentriq
- The global antibiotic crisis: a 2020 perspective
- COVID-19 delays Pfizer, Mylan’s generics merger and spin-out
PMHub
bmore group
OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....
Latest intelligence
- The global antibiotic crisis: a 2020 perspective
- A report from the CDC says the ‘approaching’ post-antibiotic era is already here...
- The role of women in science and technology
- Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
- China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
- China secures a place at the forefront of innovative medicine...
Quick links
Infographics
